By doing a lazy Friday arvo chatgdp search current SoC for GBM after surgery is Temozolomide which is worth around $200m in sales. Patent expiry was in 2013 before which annual sales were approx $920 million. So one could take a 3-5x sales figure from that and discount what you think is appropriate for the trial stage. My hope and guess would be well north of $15m.
By doing a lazy Friday arvo chatgdp search current SoC for GBM...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.01M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.6¢ | $4.463K | 273.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 3526343 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 702000 | 3 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| CHM (ASX) Chart |